Posted by shutah on February 20, 2011
It’s Sunday, 20 February 2011
51 days into the year
43 incidents listed already
Does anyone care?
HOW LONG MUST THIS LIST GET BEFORE GOVERNMENTS AND PHARMACEUTICAL COMPANIES ACKNOWLEDGE THE GLOBAL PROBLEMS SURROUNDING SSRIs?
IT’S NOT ABOUT MONEY, STOCKS, SHARES!
IT’S ABOUT HUMAN LIFE
STOP * LOOK * LISTEN
Posted in GlaxoSmithKline, GSK, MHRA, SSRIs | Tagged: Big Pharma, Criminal, FDA, GlaxoSmithKline, Government, GSK, Judiciary, Justice, Mental Health, MHRA, Parliament, SSRIs, suicide | Leave a Comment »
Posted by shutah on February 19, 2011
Surely, one of the proudest moment’s in Bob Fiddaman’s quest for justice in the eternal fight against SSRI’s .
As Bob writes in his blog “What could piss off GlaxoSmithKline more than Bob Fiddaman getting an award for basically highlighting their dark history?”
Way to go Fiddy!!!!!!
[Click the pic to read the full story]
Posted in Blogroll, Depression, GlaxoSmithKline, GSK, Health, Paroxetine, Paxil, Seroxat, SSRIs | Tagged: Antidepressants, Big Pharma, GlaxoSmithKline, GSK, psychiatry, SSRI, SSRIs | 1 Comment »
Posted by shutah on January 25, 2011
Whoopy bloody dooooo!!! Not before time that they [GSK] started to take some responsibility for their actions (inactions)!!!!
GlaxoSmithKline is pulling ads for its erectile dysfunction drug Levitra. And it’s making a big show of that choice; North American President Deirdre Connelly said it’s part of the company’s new push to be more transparent and operate with integrity. “When we walk into your home through television, we have to do it in a respectful way,” Connelly said to the Wall Street Journal.
Basically, Connelly lumped the Levitra ad move in with GSK’s ongoing campaign to break with the past, which has been sullied by off-label marketing allegations, whistleblower suits, safety questions and quality problems. And when GSK took a $3.4 billion charge for legal liabilities–including lawsuits over the recently restricted diabetes drug Avandia and a potential Justice Department settlement in an off-label marketing probe–some industry observers pegged the move as an attempt to start fresh. That charge came on top of last year’s $750 million manufacturing settlement, another longtime battle put to rest.
The company has done some other things aimed at the integrity target. It set up public databases of its payments to doctors and medical schools, and its educational and charitable grants. It changed the rules on funding continuing medical education. It just got rid of sales-related bonuses for reps, hoping that a broader job-performance focus will play well with patients and doctors–and perhaps to offset suspicions that could arise with an off-label marketing settlement. GSK has also cut prices in the developing world to give poor people easier access to medicines, a move CEO Andrew Witty has touted repeatedly. The message is clear–we’re doing business differently now.
Posted in GlaxoSmithKline, GSK | Tagged: Avandia, Big Pharma, GlaxoSmithKline, GSK, Paxil, Pharma, Seroxat, SSRIs | Leave a Comment »
Posted by shutah on January 22, 2011
More than 60 people in Britain who say they have become hooked on the anti-depressant Seroxat – a drug in the Prozac class – are exploring the possibility of legal action against the pharmaceutical company which they claim failed to warn doctors that that it could create dependency.
Two firms of solicitors say they already have between 30 and 40 cases each. The people have come forward following news of a legal case in the US in which 35 people allege they suffered severe side-effects when they tried to stop taking the drug.
The Los Angeles law firm Baum, Hedlund, Aristei, Guilford and Schiavo – which filed its action against the British manufacturers GlaxoSmithKline in September – has since had more than 2,000 calls from people to tell of their addiction to the drug, which is known in the US as Paxil. The side-effects they suffer when they try to stop taking the tablets, include jolting pains in the head, vertigo, loss of coordination, abdominal discomfort, agitation and confusion.
The US lawyers have asked GSK to set up treatment centres to help people attempting to withdraw from Paxil/Seroxat. GSK say there is no reliable scientific evidence that the drug causes addiction or dependency.
The British solicitors, Ross & Co, based in the Wirral, and Hugh James Ford Simey of Cardiff, have been receiving calls from people who did not realise that others had suffered the same symptoms when they tried to cut down and come off the drug.
“We have been contacted by 30 to 40 people, most of whom have startlingly similar tales to tell of being put on the drug and being taken off it, and then going back on,” said Mark Harvey of Hugh James Ford Simey.
Mr Harvey said most people are told by the doctor that their problems are the symptoms of their depression re-appearing and do not suspect that the drug might be to blame. “This does have the smell of something that is a problem,” he said. “The patient information sheet says it is not addictive twice.”
Graham Ross, of Ross & Co, thinks that there is a good potential case against the manufacturers. “So far as evidence of dependency is concerned, that is pretty strong,” he said.
“I feel we can prove that. Failure to ensure that GPs are aware of that risk and therefore warn patients accordingly – there is plenty of evidence that they are not doing that.”
But group actions face particular problems in Britain. Attempts to litigate against the makers of benzodiazapines – including Valium, Librium and Ativan, which were also said not to be addictive when they were launched – collapsed because the legal aid granted to the claimants was used up in the lengthy investigations of the cases demanded by the companies before the action reached court.
Posted in GlaxoSmithKline, GSK, Paroxetine, Paxil, Seroxat, Seroxat Legal, SSRIs, Withdrawal | Tagged: Antidepressants, GlaxoSmithKline, GSK, Litigation, Paroxetine, Paxil, Seroxat, SSRI, Withdrawal | 1 Comment »
Posted by shutah on January 12, 2011
10 The Seroxat litigation: Sandra Bailey & Ors v GlaxoSmithKline UK
A group action against GlaxoSmithKline UK where claimants are alleged to have suffered withdrawal effects when reducing, discontinuing or attempting to discontinue use of the anti-depressant Seroxat, and that such effects amount to personal injury.
- Hugh James partner partner Mark Harvey instructed 7 Bedford Row’s Simeon Maskrey QC and Julian Matthews.
- Addleshaw Goddard partner John Kelleher instructed Henderson Chambers’ Charles Gibson QC, Prashant Popat QC and Andrew Kinnier to represent GlaxoSmithKline UK.
Hearing date: February for 12-14 weeks.
Judge and court: Mr Justice MacKay; Queen’s Bench Division.
BRING IT ON !!!!!
Posted in GSK, Hugh James Solicitors, Paxil, Seroxat, Seroxat Legal | Tagged: Addiction, Litigation, Paxil, Seroxat, SSRI, Withdrawal | Leave a Comment »